Posted by Michael Wonder on 05 Aug 2015
Health Canada approves Stivarga (regorafenib) as a new treatment option for patients with GIST, a rare form of sarcoma
Bayer has announced Health Canadaâs expanded approval of Stivarga (regorafenib) to include its use for the treatment of adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who have had disease progression on or intolerance to treatment with imatinib mesylate and sunitinib malate. Stivarga was approved by Health Canada in March 2013 for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. For more details, go to: http://www.bayer.ca/files/Stivarga%20GIST%20Launch%20News%20Release%20ENGLISH%20Final.pdf
Posted by:
Michael Wonder
Posted in:
